Vyome Holdings Inc (HIND)

$3.01 -0.10 (-3.22%)
Market Cap 18.23M
Revenue (ttm) 8.01M
Net Income (ttm) -7.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89.01%
Debt to Equity Ratio 0.00
Volume 12,027
Avg Vol 45,026
Day's Range N/A - N/A
Shares Out 5.64M
Stochastic %K 12%
Beta 1.06
Analysts Strong Sell
Price Target $15.00

Company Profile

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 973-832-8147
Address:
Harvard Square, One Mifflin Place Suite 400, Cambridge, United States
RuneLite
RuneLite Jan. 13 at 7:23 PM
$HIND Positive 'Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval' whens the next time you think we'll get an update???
0 · Reply
ThoughtsOnThis
ThoughtsOnThis Jan. 13 at 7:22 PM
$HIND
0 · Reply
CoopersCup
CoopersCup Jan. 13 at 7:22 PM
$HIND Just started following these guys! Couple of the lads in a cord im in were chatting about them so figured I'd stay in the loop
0 · Reply
Magnificent77
Magnificent77 Jan. 13 at 4:47 PM
$HIND Now i've seen these guys pop up on reddit a handful of times in the past week.. anyone in on this?
0 · Reply
Dexter79
Dexter79 Jan. 13 at 4:38 PM
$HIND it's not a shame. It's a big shame....
0 · Reply
Tunes444
Tunes444 Jan. 13 at 2:32 PM
$HIND
0 · Reply
VyomeInc1
VyomeInc1 Jan. 13 at 12:33 PM
$HIND Dr. Aditya Bardia, a respected medical oncologist behind multiple successful oncology drugs, is guiding Vyome’s VT-1953 program. He’s speaking openly about the huge unmet need in malignant fungating wounds — a condition with no FDA-approved treatments today. Positive Phase 2 data + experienced clinical guidance = focused execution ahead. https://x.com/newvenkat/status/2010775349253075339?s=46&t=HS4i4G7lKqNAyo24R7gzDQ #Biotech #Oncology #UnmetNeed
0 · Reply
Robertcomp01
Robertcomp01 Jan. 12 at 7:40 PM
$HIND will this ever come back, if so how long?
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 1:56 PM
Pre Market Top Gainers PT2 $JAGX $HIND $BDSX $OM.X $ABVX
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 1:29 PM
$HIND look who’s up.. ⬆️
0 · Reply
Latest News on HIND
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Dec 22, 2025, 8:00 AM EST - 23 days ago

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Dec 8, 2025, 8:00 AM EST - 5 weeks ago

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Nov 25, 2025, 7:00 AM EST - 7 weeks ago

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Nov 18, 2025, 7:00 AM EST - 2 months ago

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

Nov 5, 2025, 10:13 AM EST - 2 months ago

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

RSLS

Vyome Holdings Announces Results of Annual Shareholder Meeting

Nov 4, 2025, 9:04 AM EST - 2 months ago

Vyome Holdings Announces Results of Annual Shareholder Meeting

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Sep 29, 2025, 7:00 AM EDT - 3 months ago

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Sep 17, 2025, 7:00 AM EDT - 4 months ago

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Sep 9, 2025, 8:30 AM EDT - 4 months ago

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Sep 4, 2025, 8:30 AM EDT - 4 months ago

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Aug 21, 2025, 7:00 AM EDT - 5 months ago

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Aug 18, 2025, 8:30 AM EDT - 5 months ago

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Aug 15, 2025, 8:00 AM EDT - 5 months ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Aug 14, 2025, 7:18 PM EDT - 5 months ago

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

RSLS

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Aug 13, 2025, 11:50 AM EDT - 5 months ago

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

RSLS

Vyome Announces New Board of Directors with Deep MIT and AI Ties

Aug 12, 2025, 9:48 AM EDT - 5 months ago

Vyome Announces New Board of Directors with Deep MIT and AI Ties

RSLS

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

Aug 7, 2025, 5:01 PM EDT - 5 months ago

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

RSLS

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Jul 24, 2025, 4:39 PM EDT - 6 months ago

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

RSLS

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

Jul 22, 2025, 8:31 AM EDT - 6 months ago

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

RSLS

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Jul 21, 2025, 2:10 PM EDT - 6 months ago

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

RSLS

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

Jul 1, 2025, 8:31 AM EDT - 7 months ago

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

Jun 27, 2025, 9:01 AM EDT - 7 months ago

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

RSLS

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Jun 26, 2025, 8:31 AM EDT - 7 months ago

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

RSLS

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

Jun 25, 2025, 8:31 AM EDT - 7 months ago

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

Jun 12, 2025, 8:25 AM EDT - 7 months ago

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

RSLS

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

Jun 9, 2025, 9:00 AM EDT - 7 months ago

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

RSLS

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

Jun 3, 2025, 8:31 AM EDT - 8 months ago

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

RSLS

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

May 21, 2025, 8:31 AM EDT - 8 months ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

RSLS

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

May 12, 2025, 8:32 AM EDT - 8 months ago

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ORLA RSLS

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

May 7, 2025, 8:31 AM EDT - 9 months ago

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

RSLS

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

May 2, 2025, 8:31 AM EDT - 9 months ago

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

Apr 28, 2025, 8:31 AM EDT - 9 months ago

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Apr 21, 2025, 8:31 AM EDT - 9 months ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

Apr 10, 2025, 5:54 PM EDT - 9 months ago

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

RSLS

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

Apr 9, 2025, 4:05 PM EDT - 10 months ago

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

RSLS

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Apr 7, 2025, 4:05 PM EDT - 10 months ago

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

RSLS

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

Mar 21, 2025, 11:35 AM EDT - 10 months ago

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

RSLS

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Mar 10, 2025, 8:31 AM EDT - 11 months ago

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

Feb 25, 2025, 8:31 AM EST - 11 months ago

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

Feb 15, 2025, 11:17 PM EST - 11 months ago

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

Feb 3, 2025, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Jan 13, 2025, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:43 PM EST - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

RSLS

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Nov 12, 2024, 4:05 PM EST - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

Nov 12, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

Nov 11, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

RSLS

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

Sep 19, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

RSLS

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 8:42 PM EDT - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript

RSLS

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Aug 13, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

RSLS

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders

Jul 19, 2024, 8:05 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders

CHUY RSLS

RuneLite
RuneLite Jan. 13 at 7:23 PM
$HIND Positive 'Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval' whens the next time you think we'll get an update???
0 · Reply
ThoughtsOnThis
ThoughtsOnThis Jan. 13 at 7:22 PM
$HIND
0 · Reply
CoopersCup
CoopersCup Jan. 13 at 7:22 PM
$HIND Just started following these guys! Couple of the lads in a cord im in were chatting about them so figured I'd stay in the loop
0 · Reply
Magnificent77
Magnificent77 Jan. 13 at 4:47 PM
$HIND Now i've seen these guys pop up on reddit a handful of times in the past week.. anyone in on this?
0 · Reply
Dexter79
Dexter79 Jan. 13 at 4:38 PM
$HIND it's not a shame. It's a big shame....
0 · Reply
Tunes444
Tunes444 Jan. 13 at 2:32 PM
$HIND
0 · Reply
VyomeInc1
VyomeInc1 Jan. 13 at 12:33 PM
$HIND Dr. Aditya Bardia, a respected medical oncologist behind multiple successful oncology drugs, is guiding Vyome’s VT-1953 program. He’s speaking openly about the huge unmet need in malignant fungating wounds — a condition with no FDA-approved treatments today. Positive Phase 2 data + experienced clinical guidance = focused execution ahead. https://x.com/newvenkat/status/2010775349253075339?s=46&t=HS4i4G7lKqNAyo24R7gzDQ #Biotech #Oncology #UnmetNeed
0 · Reply
Robertcomp01
Robertcomp01 Jan. 12 at 7:40 PM
$HIND will this ever come back, if so how long?
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 1:56 PM
Pre Market Top Gainers PT2 $JAGX $HIND $BDSX $OM.X $ABVX
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 1:29 PM
$HIND look who’s up.. ⬆️
0 · Reply
switchblade0611
switchblade0611 Jan. 12 at 12:16 PM
$HIND this stock has had the piss taken from them. Where there's smoke there is Fire
0 · Reply
Tunes444
Tunes444 Jan. 7 at 3:47 PM
$HIND Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
0 · Reply
TrophicTrader
TrophicTrader Dec. 25 at 12:22 PM
$HIND The next leg of valuation movement will likely hinge on how management navigates competing priorities. Commercial adoption must become steadier to neutralize skepticism around sustainability. Missed checkpoints may compound into higher capital costs. Risk remains manageable if management converts plans into consistent outputs.
1 · Reply
OlindoFL
OlindoFL Dec. 24 at 3:40 PM
$HIND LOL that there are still Sunshine Pumpers for this steaming turd! 💩
0 · Reply
DARKP00L
DARKP00L Dec. 22 at 1:10 PM
$HIND 08:06 on Dec. 22 2025 Vyome Holdings Subsidiary, LiveChain, To Acquire Senior Secured Note In Humanyze; LiveChain To Issue Shares Of ~$325K In Exchanve #tradeideas
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 22 at 1:00 PM
$HIND Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
0 · Reply
HumanityFirst
HumanityFirst Dec. 17 at 2:29 AM
$HIND anyone who was involved in this scam against retail investors - see you in court.
1 · Reply
HumanityFirst
HumanityFirst Dec. 10 at 4:33 AM
$HIND The asset sale was a major fraud against investors.
1 · Reply
Shane393
Shane393 Dec. 9 at 7:36 PM
$HIND what a fukin scam Reshape 2.0
0 · Reply
Fl1p_M0p_GaZ
Fl1p_M0p_GaZ Dec. 9 at 3:18 PM
$HIND When I see Next NRG holding this $7M+ monthly zone and stacking triple-digit YoY rates while Q3 already hit $22.9M up 232% YoY, I think the long-term multiple expansion story becomes more plausible with each new update 🚀
0 · Reply
tWiStY_JaMbOx
tWiStY_JaMbOx Dec. 9 at 3:18 PM
$HIND I’m stacking the Next NRG receipts not just the headline $7.51M November +271% YoY vs $2.02M on top of $7.39M October +196% vs $2.50M is the kind of 2-month combo that builds real long-term trust 🚀
0 · Reply
Shane393
Shane393 Dec. 8 at 10:48 PM
$HIND Vyome says "Huge step forward" these guys are desperate trading at 1/3 of what reshape was worth. Month pivots show this is going down more it simply popped a few cents above previous month value to take more victims here so short away.
0 · Reply